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Abstract: The bacterial biofilm formation in the oral cavity and the microbial activity around the 
implant tissue represent a potential factor on the interface between bone and implant fixture that 
could induce an inflammatory phenomenon and generate an increased risk for mucositis and peri-
implantitis. The aim of the present clinical trial was to investigate the bacterial quality of a new 
antibacterial coating of the internal chamber of the implant in vivo at six months. The PIXIT 
implant (Edierre srl, Genova Italy) is prepared by coating the implant with an alcoholic solution 
containing polysiloxane oligomers and chlorhexidine gluconate at 1%. A total of 15 healthy 
patients (60 implants) with non-contributory past medical history (nine women and six men, all 
non-smokers, mean age of 53 years, ranging from 45–61 years) were scheduled to receive bilateral 
fixed prostheses or crown restorations supported by an implant fixture. No adverse effects and no 
implant failure were reported at four months. All experimental sites showed a good soft tissue 
healing at the experimental point times and no local evidence of inflammation was observed. Real-
Time Polymerase Chain Reaction (PCR) analysis on coated and uncoated implants showed a 
decrease of the bacterial count in the internal part of the implant chamber. The mean of total 
bacteria loading (TBL) detected in each PCR reaction was lower in treated implants (81038 
units/reaction) compared to untreated implants (90057 units/reaction) (p < 0.01). The polymeric 
chlorhexydine coating of the internal chamber of the implant showed the ability to control the 
bacterial loading at the level of the peri-implant tissue. Moreover, the investigation demonstrated 
that the coating is able to influence also the quality of the microbiota, in particular on the species 
involved in the pathogenesis of peri-implantitis that are involved with a higher risk of long-term 
failure of the dental implant restoration. 
Keywords: peri-implantitis; implant dentistry; coating; chlorhexidine gluconate; bacterial loading  
1. Introduction 
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Dental implants are widely used to rehabilitate the edentulous area [1–3]. Implant 
rehabilitation is completely successful when there is no bone resorption around the implant fixture 
[4–6]. Lee et al. indicated that prosthetic loading or bacterial infection could be related to the 
implant failure and they reported that the prevalence of mucositis is 29.48% and that of peri-
implantitis is 9.25% [7]. 
Osseointegration can be affected by oral conditions, in particular, the micro-gap at the 
implant–abutment connection (IAC) represents a site for dental plaque aggregation favoring 
bacterial leakage, which can increase inflammatory cells at the level of the IAC, causing peri-
implantitis [8,9]. Two-piece implants unavoidably present a micro-gap between the implant and the 
abutment. These spaces, once early colonized, may constitute a bacterial reservoir that could 
subsequently contaminate the implant’s surroundings and interfere with the peri-implant tissues’ 
health. The presence of a micro-gap, and thus a reservoir of bacteria, when in close relation to the 
bone, may have a role in bone loss [10].  
The bacteria found at the IAC level can be both anaerobic and facultatively anaerobic, 
depending on the features of the microhabitat. In addition, patients at risk of periodontal disease 
have a higher risk of peri-implantitis [11]. Periodontopathogenic bacteria and in particular the 
species of “red complex” (porphyromonas gingivalis, tanerella forsythia, treponema denticola), and other 
bacteria, such as Corinebacterium rectus and Fusobacterium nucleatum, cause peri-implant tissue 
inflammation, which may lead to the destruction of the peri-implant bone, resulting in implant loss 
[12]. The treatment of peri-implantitis has unpredictable results, while the control of bacterial 
plaque is crucial [12]. Peri-implantitis is usually associated with gram-negative bacteria similar to 
those that cause periodontal disease [11,12]. Peri-implantitis, such as periodontal disease, is the 
result of bacterial insult and the subsequent host response. Some studies have shown that bacterial 
species of periodontal disease are very similar to those that cause peri-implantitis[11–13]. 
In this way, it has been reported that a clinical history of periodontitis is related with a higher 
risk for peri-implant infections [11,12].  
Different analytical methods have been used for a microbiological characterization of microbial 
species and bacterial quality in peri-implantitis [14]. Polymerase chain reaction (PCR) method is 
reported as rapid and cost-sensitive for a microbial quantitative evaluation of the oral biofilm and it 
is able to determine the total bacteria loading (TBL) and identify different bacterial species of the 
cluster related to the peri-implantitis, such as Corinebacterium rectus and Fusobacterium nucleatum 
[14–18]. Many different methods have been described to increase the peri-implant tissue healing 
and minimize the inflammation reaction around the dental implant fixture. 
The prosthetic connection between implant and abutment interface could represent a critical 
point for a potential microbial colonization that is able to feed an infection and an inflammatory 
reaction at the level of the peri-implant interface [9]. 
It has been reported that treatment with an antibacterial coating characterized by chlorhexidine 
gluconate is able to reduce the bacterial loading in vitro [15]. 
The aim of the present clinical trial was to investigate the antibacterial activity of a new 
antibacterial coating of the internal chamber of the implant in vivo at six months. 
2. Materials and Methods 
2.1. PIXIT Implants 
The PIXIT implant (Edierre srl, Genova, Italy) is produced by coating the internal part of the 
implants with an alcoholic solution containing polysiloxane oligomers and chlorhexidine gluconate 
at 1%. 
The product has the ability to bind the titanium surface via interaction of the OH– 
functionalities present on the polisyloxane chains and the titanium surface (antimicrobial coating 
composition for dental implant, PCT/IT2015/000142). The role of the alkyl chains present on the 
siloxane units is that of trapping, through Van der Waals interactions, chlorhexidine molecules, 
allowing their subsequent slow release when in contact with the aqueous medium. 
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The coating of the internal chamber of the implants was produced by filling with the PIXIT 
solution which was left in contact with the surface for at least 10 min followed by draining and 
implant heating at 60 °C for 45 min. The coating of abutment, healing cups, and screws was 
obtained by immersion in PIXIT solution for 10 min followed by centrifugation on a sintered glass 
filter and subsequent heating at 60 °C for 45 min. This protocol was used for the first time in a 
clinical study. The coating treatment of the implant junction has been tested in a previous in vitro 
study by Lauritano et al. that reported no bacterial growth at the level of the internal chamber [15]. 
Moreover, the author reported a continuous release from PIXIT of chlorhexidine in the medium, 
producing an active action over time of the coating [15]. 
2.2. Antimicrobical Test 
Healing cups (Edierre srl) were tested for bacterial leakage. Ten healing caps signed as tests 
and numbered with 15, 16, 19, 20, 24, 25, 26, 30, 31, 32 and ten healing caps signed as controls and 
numbered with 13, 14, 17, 18, 21, 22, 23, 27, 28, 29, were tested. The caps were inserted in Petri 
dishes and contaminated with 100 μLT of a microbial pool consisting of Gram positive and negative 
bacteria (Staphilococcus aureus, Pseudomonas aeruginosa, Escherichia coli, Enterococcus hirae) and 
Candida albicans in a concentration range of 1–5 × 105 cfu/mL. After a 10 min contact time, 18 mL of 
LB Agar were inserted, and the plates were incubated at 37 °C for 24 h. Contamination was also 
performed in duplicate on Petri dishes that did not contain healing caps. 
2.3. Population Inclusion 
The protocol for this study was designed in accordance with the Helsinki Declaration (revised 
version of Tokyo at 2004) and Good Clinical Practice Guidelines. The Inter Institutional Ethics 
Committee of Faculdade Ingá, UNINGÁ, PR, BRAZIL, No. 153455/2018; CAEE 
04609518.6.0000.5220, approved it. 
A total of 15 healthy patients (60 implants) with non-contributory past medical history (9 
women and 6 men, all non-smokers, mean age of 53 years, ranging from 45–61 years) were included 
in this study. All patients’ candidates were scheduled to receive bilateral fixed prosthesis or crown 
restorations supported by implant fixture. The subjects were randomly allotted for each group test 
and control. All patients signed a written informed consent form.  
The subjects were treated at the Department of Oral Implantology, Center for Advanced 
Studies, Dental Research Division, UNINGÁ Cachoeiro de Itapemirim, Brazil. All patients 
underwent a preliminary examination and they underwent Orthopanoramic radiographs and 3D 
Cone Beam for the surgical treatment planning. 
The inclusion criteria were: Edentulous or partly edentulous patients with a unilateral or 
bilateral loss of teeth, with severe alveolar atrophy and a residual alveolar ridge height of between 2 
and 4 mm. The exclusion criteria were: Severe illness, head and neck radiation therapy, 
chemotherapy, uncontrolled diabetes, uncontrolled periodontal disease, and smoking. Exclusion 
criteria also included facial or neck inflammatory skin diseases, carotid sinus hyperesthesia, 
hyperthyroidism, and patients who unilaterally declined undergoing post-operative treatment. 
2.3. Surgical Procedure 
The subjects received prophylactic antibiotic therapy: Two grams of amoxicillin (or 
clindamycin 600 mg if allergic to penicillin) 1 h before surgery, and they were instructed to rinse 
with chlorhexidine 0.2% (Curasept, Saronno Italy) for 1 min. All patients were treated under local 
anesthesia. The standard implant site preparation procedure, as recommended by the implant 
manufacturer, was used. Implants were placed 2 mm under the crestal bone level. Ibuprofen 400 
mg was prescribed two to four times daily during meals, for as long as required. Patients were 
instructed to use chlorhexidine 0.2% mouthwash for 1 min twice daily for 2 weeks, and to avoid 
brushing and trauma on surgical sites. Postoperative antibiotics were prescribed only to patients 
who received bone augmentation procedures: Amoxicillin 1 g twice daily for 6 days. Patients 
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allergic to penicillin were prescribed clindamycin 300 mg twice daily for 6 days. Within 1 week all 
patients were recalled and checked. Implants were exposed and healing screws placed in the 
implant after 4 months. Within a further 10 days all patients were recalled, healing screws removed, 
and a sample of the implant internal chamber microbiota was obtained from a single site by a paper 
probe. DNA was extracted and purified using standard protocols that include two consecutive 
incubation with lysozyme and proteinase K, followed by spin-column purification. Healing screws 
were repositioned at 20 Ncm, and recommended manufacturer values were used. 
2.4. Real-Time Polymerase Chain Reaction 
Primers and probes oligonucleotides were designed based on 16S rRNA gene sequences of the 
Human Oral Microbiome Database (HOMD 16S rRNA RefSeq Version 10.1) counting 845 entries 
(Biomers.net GmbH, Ulm, Germany). All the sequences were aligned in order to find either a 
consensus sequence or less conservate spots. Three real-time PCR runs were performed for each 
sample. 
The first reaction quantified the total amount of bacteria using two degenerate primers and a 
single probe matching a highly conservated sequence of the 16S ribosomal RNA gene. The second 
reaction detected and quantified the three red complex bacteria, i.e., Porphyromonas gingivalis, 
Tannerella forsythia, Treponema denticola, in a multiplex PCR. The third reaction detected and 
quantified two members of the orange complex Fusobacterium nucleatum and Campylobacter rectus 
and a member of purple complex Aggregatibacter actinomycetemcomitans. These reactions included a 
total of six primers and three probes that were highly specific for each species. Table 1 shows probe 
and primer sequences used for the amplification. Oligonucleotide concentrations and PCR 
conditions were optimized to ensure sensitivity, specificity, and no inhibitions in case of 
unbalanced target amounts. Absolute quantification assays were performed using the Applied 
Biosystems 7500 Sequence Detection System. The amplification profile was initiated by a 10 min 
incubation period at 95 °C to activate polymerase, followed by a two-step amplification of 15 s at 95 
°C and 60 s at 57 °C for 40 cycles. All these experiments were performed including non-template 
controls to exclude reagents contamination. 
Plasmids containing synthetic DNA target sequences (Eurofin MWG Operon, Ebersberg 
Germany) were used as standard for the quantitative analysis. 
Standard curves for each target were constructed in a triplex reaction, by using a mix of the 
same amount of plasmids, in serial dilutions ranging from 101 to 107 copies. There was a linear 
relationship between the threshold cycle values plotted against the log of the copy number over the 
entire range of dilutions (data not shown). The copy numbers for individual plasmid preparations 
were estimated using the Thermo NanoDrop spectrophotometer. 
The absolute quantification of total bacterial genome copies in samples allowed for the 
calculation of a relative amount of red complex species. To prevent samples and PCR 
contamination, plasmid purification and handling was performed in a separate laboratory with 
dedicated pipettes. 
Table 1. Probe and primer sequences use for periodontal bacteria amplification. 

























Cr f-TGACGCTAATGCGTGAAAGC  TACCCTGGTAGTCCACGCCCTA
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r-CTCGACTAGCGAAGCAACAACTAG AACGA 
TBL 




Aa: Aggregatibacter actinomycetemcomitans; Pg: Porphyromonas gingivalis; Tf: Tannerella forsythia; Td: 
Treponema denticola; Fn: Fusobacterium nucleatum; Cr: Campylobacter rectus; TBL: Total bacterial load. 
2.5. Statistical Analysis 
The non–parametric Wilcoxon signed rank test was used because data were not normally 
distributed. 
3. Result 
3.1. Clinical Results 
A total of 60 implants were positioned, 30 test (implants treated with PIXIT) and 30 control 
(untreated implants). No adverse effect and no implant failure were reported at four months. All 
experimental sites showed a good soft tissue healing and no local evidence of inflammation was 
reported. PCR analysis was performed only in 52 implants (26 treated and 26 untreated implants). 
PCR analysis on coated and uncoated implants showed a decrease of the bacterial count in the 
internal part of the implant chamber. The total bacterial load was evaluated by absolute 
quantification of a conserved ribosomal 16S gene sequences, using a degenerated primers-probe set. 
The mean of total bacteria loading (TBL) detected with PCR reaction was lower in treated implants 
(81038 units/reaction) compared to untreated implants (90057 units/reaction) (Tables 2 and 3). A 
Wilcoxon signed rank test showed that the effect of treatment was significant (Z = −3.19, p = 0.001) 
(Tables 4 and 5). Similar results were obtained when amounts of a single bacterial specie was 
investigated: Corinebacterium rectus (Z = −2.75, p = 0.006) and Fusobacterium nucleatum (Z = −3.74, p = 
0.001). Postoperative antibiotics were prescribed only to patients who received bone augmentation 
procedures and only during the implant placement. No antibiotics were prescribed during the 
healing screws placement.  
Table 2. Bacterial count observed for treated with the alcoholic solution containing polysiloxane 
oligomers and chlorhexidine gluconate at 1% (PIXIT) and untreated implants. 
 N Min Max Mean SD 
Fn-U 26 0 1639 410 393 
Cr-U 26 0 2387 914 758 
Cr-T 26 0 192 59 66 
Fn-T 26 0 228 81 79 
TBL-T 26 37192 149707 81038 45146 
TBL-U 26 40013 191064 90057 53788 
Fn: Fusobacterium nucleatum; Cr: Campylobacter rectus; TBL: Total bacterial load; T: Treated implants; 
U: Untreated implants. 
Table 3. Statistical analysis in order to verify the distribution of samples. a Lilliefors Correction. 
 Kolmogorov-Smirnovaa Shapiro-Wilk 
 Stat df p Value Stat df p Value 
Fn-T 0.188 26 0.019 0.857 26 0.002 
Cr-T 0.314 26 0.000 0.810 26 0.000 
Cr-U 0.270 26 0.000 0.843 26 0.001 
Fn-U 0.191 26 0.016 0.874 26 0.004 
TBL-T 0.330 26 0.000 0.732 26 0.000 
TBL-U 0.304 26 0.000 0.772 26 0.000 
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Table 4. Non Parametric Test. Wilcoxon test. Distribution of ranks. a. FN-U < FN-T; b. FN-U > FN-T; 
c. FN-U = FN-T; d. CR-U < CR-T; e. CR-U > CR-T; f. CR-U = CR-T; g. TBL-U < TBL-T; h. TBL-U > 
TBL-T; i. TBL-T = TBL-T. 
  N Mean rank Sum 
 Neg Rank 4 a 3.75 15.00 
 Pos Rank 19 b 13.74 261.00 
FN-U – FN-T Equal values 3 c   
 Tot 26   
 Neg Rank 2 d 5.75 11.50 
 Pos Rank 13 e 8.35 108.50 
CR-U – CR-T Equal values 11 f   
 Tot 26   
 Neg Rank 7 g 7.14 50.00 
 Pos Rank 19 h 15.84 301.00 
TBL-U – TBL-T Equal values 0 i   
 Tot 26   
Table 5. Output of Wilcoxon test. a. Wilcoxon test. b. Based on negative ranks. 
 FN-U – FN-T CR-U – CR-T TBL-U – TBL-T 
Z −3.741 b −2.755 b −3.187 b 
Sig. Asint. a 2 code 0.000 0.006 0.001 
3.2. Antimicrobical Test Results 
The coating treatment of the implant junction has been tested in a previous in vitro study by 
Lauritano et al. that reported no bacterial growth at the level of the internal chamber [15]. Moreover 
the author reported a continuous release from PIXIT of chlorhexidine in the medium, producing an 
active action over time of the coating [15] (Figure 1). 
 
Figure 1. Internal chamber of the fixtures of untreated (left) and treated (right) with the alcoholic 
solution containing polysiloxane oligomers and chlorhexidine gluconate at 1% (PIXIT) showing that 
the coating does not change the internal thickness. 
Figure 2 shows no bacterial growth after treatment with PIXIT in the test dish. Since the 
correlation between numbered samples marked as test and controls is not known, an average value 
of the microbial charge developed in the control plates was evaluated and with respect to this value 
the reduction of the microbial load which developed in the Petri containing the tests was calculated. 
In all cases, a considerable reduction of the microbial development in tests compared to samples 
was observed, in particular the inhibition of the microbial growth was 99% in test sample 15, 95% in 
test 32, 90% in test 25, 80% in the tests 16, 26, 24 and 31, 60% in test 30, 40% in test 19 and 30% in test 
20. 
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Figure 2. Control (left) and test (right) healing cups showing the absence of microbial growth in the 
presence of a contamination of the order of 1–5 × 104 cfu of gram positive, gram negative, and 
Candida. 
4. Discussion 
Dental implants are an excellent treatment option for restoring areas that are missing one or 
more teeth. The majority of dental implants have two components: The implant placed in the bone 
during the surgical procedure, and the abutment, screwed into the implant to support the 
prosthetic rehabilitation. These two-piece implant systems present slots and cavities between the 
implant and the abutment that can act as a trap for bacteria causing the accumulation of pathogens 
and the onset of peri-implantitis. During the prosthetic rehabilitation, bacterial dissemination is 
unavoidable, and when the IAC is located at the level of the bone crest, the formation of biofilms in 
this area causes bone resorption, observed in the early stages of prosthetic load. Bacterial loading is 
an important factor in peri-implantitis, occurring during soft tissue manipulation of prosthetic 
rehabilitation. It is clear that peri-implantitis occurs due to the presence of pathogenic 
microorganisms colonizing the surrounding implant area and the suppression or eradication of 
these microbes prevents peri-implantitis. The main cause of peri-implantitis consists in the passage 
of pathogenic bacteria in the abutment-implant gap. The inner spaces are easily colonized, and 
bacteria may leak out from these spaces through the IAC into the peri-implant area. Peri-implantitis 
is usually associated with gram-negative bacteria similar to those that cause periodontal disease. 
Covering IAC surfaces with coatings, by adding biomimetic bioactive substances to improve its 
biological characteristics, has also been recently investigated [15]. Modifications of IAC using 
various modalities aim to improve prevention of bacterial infection and promote faster healing 
times. These aspects are of paramount importance in modern dentistry, since immediate or early 
loading has become a predictable treatment protocol.  
The presence of a micro gap at the IAC is well known and varies from 1 to 49 μm according to 
different implant systems and colonization of IAC may cause peri-implant bone resorption [16,17]. 
The IAC is usually situated under the soft tissue of the gingiva, sometimes very near to the bone. 
For this reason, the control of bacterial leakage through the IAC can be a major aspect in preventing 
the infection of the peri-implant tissues. In patients with previous periodontal diseases, the 
reduction of the passage of pathogenic bacteria should be considered as important, especially 
because studies have shown that bacterial species of periodontal disease are very similar to the 
bacteria that cause peri-implantitis [18]. The clinician should keep in mind that the presence of a 
pathogenic microflora in an initial phase can be associated with a higher risk of peri-implantitis, as 
per periodontal diseases.  
The prevention of the microbial infection at the level of the implant junction appears the key 
point for the healing of the peri-implant tissue and a long term maintaining of the dental implant 
restoration [19–22]. 
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The coating treatment of the implant junction has been tested in a previous in vitro study by 
Lauritano et al. that reported no bacterial growth at the level of the internal chamber [15]. Moreover 
the author reported a continuous release from PIXIT of chlorhexidine in the medium, producing an 
active action over time of the coating [15]. The protocol adopted in the present study exclude the 
effect of antibiotic on bacteria proliferations in both groups. The antibiotics used during the implant 
surgery did not cause a bias in the results because no preoperative o postoperative antibiotics were 
prescribed during the healing screws placement. In fact, the use of a mucoperiosteal flap in implant 
surgery does not represent a significant risk for developing bacteremia [23]. Antibiotic prophylaxis 
in surgery is only indicated when surgery is performed in infected sites, when large foreign 
materials are implanted, in patients who are at risk of infectious endocarditis, and immuno-
compromised patients [24,25].  
In conclusion, the polymeric coating trapping chlorhexidine in the internal chamber of the 
implant showed the ability to control the bacterial loading at the level of the peri-implant tissue. 
Moreover, the investigation demonstrated that the coating is able to influence also the quality of the 
microbiota, in particular on the species involved in the pathogenesis of peri-implantitis that are 
involved with a higher risk of long-term failure of the dental implant restoration. 
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